SLC6A1: A TRP Transporter Implicated in Sleep, Anxiety and Depression

Target Name: SLC6A1

NCBI ID: G6529

SLC6A1

SLC6A1: A TRP Transporter Implicated in Sleep, Anxiety and Depression

GABA transporter 1 (SLC6A1) is a protein that is expressed in the brain and plays a critical role in the transportation of GABA, a neurotransmitter that is involved in a wide range of physiological processes, including sleep, anxiety, and depression. SLC6A1 is also known as GABA transporter alpha, and it is a member of the subfamily of transporters known as the transfer RNA-protein fusion (TRP) transporters.

The TRP transporters are a family of proteins that have been identified as potential drug targets for a variety of psychiatric and neurological disorders. These transporters are characterized by the presence of a nucleotide-binding oligomerization domain (NBD), which is responsible for the binding of neurotransmitters to the transporter. SLC6A1 is a classic example of a TRP transporter, with a NBD that is able to bind GABA with high affinity.

SLC6A1 is expressed in the brain and is involved in the transport of GABA across the blood-brain barrier (BBB). The BBB is a specialized barrier that is designed to prevent the entry of certain molecules into the brain, including toxins and medications that are harmful to the brain. SLC6A1 is thought to play a key role in breaking down the barrier and allowing GABA to enter the brain.

Studies have shown that SLC6A1 is often expressed at higher levels in individuals with schizophrenia, a disorder that is characterized by the presence of hallucinations, delusions, and disorganized thinking. Additionally, individuals with depression and anxiety are also thought to have increased expression of SLC6A1.

Furthermore, SLC6A1 has been shown to play a role in the regulation of sleep. Studies have shown that SLC6A1 is involved in the transport of GABA to the brainstem, where it is involved in the regulation of sleep-wake cycles. This suggests that SLC6A1 may be a potential drug target for insomnia and other sleep disorders.

In addition to its role in the regulation of sleep, SLC6A1 is also involved in the regulation of anxiety and depression. Studies have shown that SLC6A1 is involved in the transport of GABA to the brain, and that this may play a role in the regulation of these disorders.

Another potential function of SLC6A1 is its role in the regulation of pain. Studies have shown that SLC6A1 is involved in the transport of GABA to the brain, and that this may play a role in the regulation of pain. This suggests that SLC6A1 may be a potential drug target for chronic pain.

In conclusion, SLC6A1 is a protein that is expressed in the brain and plays a critical role in the transportation of GABA, a neurotransmitter that is involved in a wide range of physiological processes. SLC6A1 is also known as GABA transporter alpha and is a member of the subfamily of transporters known as the transfer RNA-protein fusion (TRP) transporters. It is expressed in the brain and is involved in the transport of GABA across the blood-brain barrier (BBB). SLC6A1 is also thought to play a key role in the regulation of sleep, anxiety, and depression, as well as pain. As a result, SLC6A1 is a potential drug target for a variety of psychiatric and neurological disorders.

Protein Name: Solute Carrier Family 6 Member 1

Functions: Mediates transport of gamma-aminobutyric acid (GABA) together with sodium and chloride and is responsible for the reuptake of GABA from the synapse (PubMed:30132828). The translocation of GABA, however, may also occur in the reverse direction leading to the release of GABA (By similarity). The direction and magnitude of GABA transport is a consequence of the prevailing thermodynamic conditions, determined by membrane potential and the intracellular and extracellular concentrations of Na(+), Cl(-) and GABA (By similarity). Can also mediate sodium- and chloride-dependent transport of hypotaurine but to a much lower extent as compared to GABA (By similarity)

The "SLC6A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets